Anita F. Das, PhD

Statistician
Das Consulting

Disclosure(s): Cidara: Advisor/Consultant; Contrafect: Advisor/Consultant; Iterum Therapeutics: Advisor/Consultant; Paratek: Advisor/Consultant; Utility therapeutics: Advisor/Consultant

Poster(s):

• (P-1092) Re-analysis of Pivmecillinam Randomized Clinical Trial Data According to 2019 US Food and Drug Administration Guidance for the Treatment of Uncomplicated Urinary Tract Infection
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1107) Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT